Artikel
Prognostic significance of influence of CD31 and PDEF expression in patients with non-small-lung cancer
Suche in Medline nach
Autoren
Veröffentlicht: | 14. Oktober 2013 |
---|
Gliederung
Text
Objective: The aims of this study were to examine prognostic significance of microvessel density (MVD) by CD31 staining and the role of pigment epithelium-derived factor (PEDF) in patients with stage IA-IIIB non-small lung cancer (NSCLC) and explore associations between MVD by CD31 expression and PEDF.
Methods: We used immunohistochemistry to examine the expression of PEDF and to evaluate MVD by CD31 in a cohort of 69 patients who had undergone radical resection for NSCLC. Detection of the stroma around the vital tumor tissue and cancer cells was given by the haematoxylin-eosin-stained sections and only these regions were the target area.
Results: Strong positive correlation coefficient for all measurements of the two independent investigators was highly significant (p<0.001). No correlation of the CD31 immunoexpression and PEDF intensity, PEDF area or PEDF area index was seen.
CD31 immunoexpression and PEDF staining have no correlation to the clinicopathologic parameters mentioned above. In survival analysis there was a significant better overall survival the higher the CD31 count are. In 29 patients (42%) the median of CD31 count was higher than the median level and the overall survival was significant better (52 ± 8 and 78 ± 10 months, log rank p=0.031). In 58 patients (84%) of cases cause of death were known as primary cancer related. In these patient cohort CD31 count above median was equally present in 44.2% (26 patients) and survival was significant longer in high CD31 count (56 ± 10 and 83 ± 10 months, log rank p=0.036). After Cox-Regression analysis CD31 count higher than the median level was an independent factor for survival. Nevertheless, there was a significant difference of PEDF intensity values between stage IB, IIA, IIB and IIIA. Additionally, we seen a significant negative correlation (T=–0.288, p=0.002) between pathologic T-stage and median PEDF area and vice versa a positive correlation (T=0.227, p=0.016) to median PEDF intensity.
Conclusion: We have independently validated CD31 and PEDF as prognostic biomarkers in NSCLC, and we demonstrate, to best of our knowledge for the first time, that MVD measured by CD31 correlates positively with better survival in patients with NSCLC. The expression of PEDF could be related to angiogenesis, but is presently not suitable for use in risk stratification of NSCLC. Further studies are needed to verify the role of MVD in anticancer therapy of NSCLC.